CY1106152T1 - Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids - Google Patents

Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids

Info

Publication number
CY1106152T1
CY1106152T1 CY20061101235T CY061101235T CY1106152T1 CY 1106152 T1 CY1106152 T1 CY 1106152T1 CY 20061101235 T CY20061101235 T CY 20061101235T CY 061101235 T CY061101235 T CY 061101235T CY 1106152 T1 CY1106152 T1 CY 1106152T1
Authority
CY
Cyprus
Prior art keywords
antitoxins
aids
prevention
treatment
application
Prior art date
Application number
CY20061101235T
Other languages
English (en)
Inventor
Jean-Francois Zagury
Jay Rappaport
Miguel Carcagno
Original Assignee
Neovacs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neovacs filed Critical Neovacs
Publication of CY1106152T1 publication Critical patent/CY1106152T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Μία ρυθμιστική πρωτεΐνη ιού ή ένα θραύσμα ρυθμιστικής πρωτεΐνης ιού ή ιντερφερόνη-α ή ένα θραύσμα της ιντερφερόνης-α η οποία είναι καρβοξυμεθυλιωμένη, μέθοδος παρασκευής, χρήση του λαμβανόμενου προϊόντος σε μία μέθοδο θεραπευτικής αγωγής του ανθρώπινου ή ζωικού σώματος, φαρμακευτική σύνθεση και εμβόλιο περιέχον, υπό τύπο δραστικού παράγοντα, μία τουλάχιστον από τις καρβοξυμεθυλιωμένες πρωτεΐνες ή θραύσματα.
CY20061101235T 1997-12-26 2006-08-31 Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids CY1106152T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9716589A FR2773156B1 (fr) 1997-12-26 1997-12-26 Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
PCT/FR1998/002727 WO1999033872A1 (fr) 1997-12-26 1998-12-14 Nouveaux immunogenes anti-hiv (toxoides), procedes de preparation et application a la prevention et au traitement du sida

Publications (1)

Publication Number Publication Date
CY1106152T1 true CY1106152T1 (el) 2011-06-08

Family

ID=9515202

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101235T CY1106152T1 (el) 1997-12-26 2006-08-31 Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids

Country Status (16)

Country Link
US (2) US6420141B1 (el)
EP (3) EP1042363B1 (el)
JP (2) JP2001527029A (el)
AR (1) AR014946A1 (el)
AT (2) ATE330970T1 (el)
AU (2) AU1568499A (el)
BR (1) BR9814473A (el)
CA (1) CA2316811A1 (el)
CY (1) CY1106152T1 (el)
DE (2) DE69835031T2 (el)
DK (1) DK1042363T3 (el)
ES (1) ES2267199T3 (el)
FR (1) FR2773156B1 (el)
MX (1) MXPA00006263A (el)
PT (1) PT1042363E (el)
WO (2) WO1999033872A1 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773156B1 (fr) 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
FR2781158B1 (fr) * 1998-07-15 2002-12-13 Vacs Internat Nouvelles proteines modifiees immunogenes non immunosuppressives, leur procede de preparation et leurs applications
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
FR2792639B1 (fr) 1999-04-26 2003-06-06 Neovacs Nouveaux immunogenes anti-vih (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
CN1326873C (zh) * 2000-01-31 2007-07-18 史密丝克莱恩比彻姆生物有限公司 用于hiv预防或治疗性免疫的疫苗
US20080044435A1 (en) * 2004-03-16 2008-02-21 Cohen David I Tat-Based Tolerogen Compositions and Methods of Making and Using Same
NO314587B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
FR2828404B1 (fr) * 2001-08-10 2005-07-15 Neovacs Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal
WO2003054006A2 (en) * 2001-12-11 2003-07-03 Aventis Pasteur Mutated hiv tat
NZ536499A (en) * 2002-05-16 2008-04-30 Bavarian Nordic As Fusion protein comprising the amino acid sequence of at least four different HIV proteins selected from Vif, Vpr, Vpu, Vpx, Rev, Tat and Nef, wherein the fusion protein is not processed to individual HIV proteins having the natural N and C termini
US20040115830A1 (en) * 2002-09-25 2004-06-17 Igor Touzov Components for nano-scale Reactor
FR2862306B1 (fr) 2003-11-17 2008-05-30 Aventis Pasteur Composition vaccinale
WO2005090968A1 (en) * 2004-03-16 2005-09-29 Inist Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
US8168165B2 (en) * 2008-12-23 2012-05-01 Abbott Laboratories Alkylated interleukin-18 compositions
CN102405057B (zh) 2009-03-23 2016-05-25 那尼尔科斯治疗公司 用免疫刺激性Hiv Tat衍生物多肽治疗癌症
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
CA2926221A1 (en) 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
SG11201701279VA (en) * 2014-08-18 2017-03-30 Sanofi Pasteur Inc Alkylated influenza vaccines
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
FR3057438B1 (fr) 2016-10-14 2020-10-02 Univ Limoges Procede d'elicitation d'une plante au moyen d'extraits de champignons macroscopiques comestibles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258029A (en) 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
ATE116006T1 (de) 1985-04-29 1995-01-15 Genetic Systems Corp Synthetische antigene zum nachweis von aids.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
WO1991018454A1 (en) * 1990-05-18 1991-11-28 Centre National De La Recherche Scientifique Compositions capable of blocking cytotoxicity of viral regulatory proteins and neurotoxic symptoms associated with retroviral infection
WO1994015634A1 (en) * 1992-12-30 1994-07-21 Matthias Rath Tat and rev oligopeptides in hiv treatment
WO1995031999A1 (en) 1994-05-23 1995-11-30 Immunogiology Research Institute, Inc. Compositions of transactivating proteins of human immunodeficiency virus
JPH11501310A (ja) * 1995-03-08 1999-02-02 ネオバック レトロウイルスの調節タンパク質から誘導された無毒の免疫原、抗体、製造方法およびそれらを含んでなる医薬組成物
US6200575B1 (en) * 1996-03-07 2001-03-13 Neovacs Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them
FR2773156B1 (fr) 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida

Also Published As

Publication number Publication date
ES2267199T3 (es) 2007-03-01
EP1041888B1 (en) 2008-10-22
EP1041888A1 (en) 2000-10-11
US6420141B1 (en) 2002-07-16
AU1939799A (en) 1999-07-19
DK1042363T3 (da) 2006-10-30
CA2316811A1 (en) 1999-07-08
WO1999033346A1 (en) 1999-07-08
ATE412006T1 (de) 2008-11-15
DE69840152D1 (de) 2008-12-04
FR2773156A1 (fr) 1999-07-02
MXPA00006263A (es) 2003-07-14
WO1999033872A1 (fr) 1999-07-08
US7022326B1 (en) 2006-04-04
BR9814473A (pt) 2001-10-23
DE69835031T2 (de) 2007-01-18
EP1042363B1 (fr) 2006-06-21
FR2773156B1 (fr) 2000-03-31
PT1042363E (pt) 2006-11-30
DE69835031D1 (de) 2006-08-03
EP1042363A1 (fr) 2000-10-11
JP2006257102A (ja) 2006-09-28
AR014946A1 (es) 2001-04-11
AU1568499A (en) 1999-07-19
ATE330970T1 (de) 2006-07-15
EP1975173A1 (en) 2008-10-01
JP2001527029A (ja) 2001-12-25
EP1041888A4 (en) 2000-10-18

Similar Documents

Publication Publication Date Title
CY1106152T1 (el) Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids
PT698108E (pt) Vectores adenovirais de origem animal e utilizacao em terapia genica
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
ATE255128T1 (de) Peptid-immitierende substanzen in der krebstherapie
DE3880766D1 (de) Konjugate von interferon alpha mit immunglobulinen.
EA200400376A1 (ru) Пептиды, полученные из казеина, и их использование в терапии
DE602004020266D1 (de) Therapeutische und diagnostische anti-hsp 70-antikörper
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
DK0588477T3 (da) Medicinsk præparat omfatende TCF-11
DK1165102T3 (da) Matrixproteinpræparater til podning i ikke-mineraliseret væv
PT983300E (pt) Sais peptidicos de bpc com actividade organo-protectora, processo para a sua preparacao e sua utilizacao em terapia
CY1108761T1 (el) Απενεργοποιημενες κυτοκινες για ανοσοποιηση
ATE108335T1 (de) Kit oder zusammensetzung zur vorbeugung oder behandlung von hiv-1 infektionen.
ATE448796T1 (de) Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein
HUP0100937A2 (hu) Többszörösen elágazó peptidkonstrukciókat tartalmazó liposzómák és alkalmazásuk humán immundeficiencia vírus ellen
CY1108412T1 (el) Συνθεσεις εμβολιου που περιλαμβανουν omp85 πρωτεϊνες απο neisseria gonorrhoea και neisseria miningitidis
DE69130571D1 (de) Peptide, die infektionen mit menschlichem immunschwächevirus hemmen und deren anwendungsweisen
EA200000011A1 (ru) Средства и способы доставки лекарственных препаратов для терапии вирусных и бактериальных инфекций и синдромов истощения
WO2003034069A3 (en) Tcmp 03 protein for use in cancer therapy
UA37445A (uk) Протизапальний засіб